Novartis is stepping back from a patent dispute over the leukaemia therapy Kymriah following opposition from a non-governmental organisation (NGO), reported Swissinfo.
Swiss NGO Public Eye is claiming victory in the European Patent Office battle, but Novartis says the patent in question was only one of several it has in place on the CAR-T cell therapy.
Public Eye, which launched the patent challenge together with Médecins du Monde earlier this year, says the therapy costs CHF 370,000, which it argues amounts to "abusive" commercial exploitation.
Meanwhile, Novartis noted that Kymriah is "covered by several patents" that protect the cost of the innovation it put into the cell therapy treatment, not just the one that has been withdrawn.
The Swiss drugmaker indicated that the patent in question "is not critical" to Kymriah's continued development and marketing, "and the decision has therefore been taken to withdraw the opposed patent."
To read more NewsPoints articles, click here.